In Q4, Regeneron reported EPS at $12.07, up from $11.86 in the same quarter last year. This print beat analysts’ estimates by 7.8%. Over the next 12 months, Wall Street expects Regeneron’s ...

Regeneron reported Q4 2024 earnings today - revenues were up 10% YoY to $3.79bn. Full-year revenues were up 8% to $14.2bn. Q4 GAAP EPS at $8.06, and $38 adj. full-year. The company declared its ...

Regeneron Pharmaceuticals, Inc. REGN delivered better-than-expected fourth-quarter 2022 results even though Eylea sales declined. Dupixent maintained its stellar performance, with progress on ...

Therefore, Regeneron’s total revenue rose by 14% in Q4 when excluding the drug. As the company made progress in research and development, its expenses increased. Research and development ...

Regeneron Pharmaceuticals reported strong Q4/2023 earnings, exceeding expectations and showing impressive growth from Dupixent and Libtayo. The company's next generation of blockbuster drugs are ...

Shares of Regeneron Pharmaceuticals, Inc. REGN declined 1.13% after the company reported disappointing fourth-quarter preliminary sales for lead drug, Eylea. Sales of Eylea (aflibercept ...

Reports Q4 revenue $3.79B, consensus $3.75B. “Regeneron’s (REGN) financial and commercial strength allows for continued investment in our industry-leading R&D pipeline, while simultaneously ...

Jan 8 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab said on Monday its franchise of eye drug Eylea recorded preliminary sales of $1.46 billion in the United States in the fourth ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) said Monday it currently expects that its financial results for the second quarter 2024 will include an acquired in-process research and ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 ...